Eris Lifesciences
Eris Lifesciences Ltd is an Indian pharmaceutical company specializing in branded generic formulations for chronic and sub-chronic therapeutic areas. The company develops, manufactures, and markets branded generic drugs targeting diabetes, cardiovascular diseases, CNS disorders, dermatology, and women's health. Revenue is principally generated through wholesale pharmaceutical product sales to medical distributors, retail pharmacy networks, and hospital groups across India. Core end markets encompass prescription patients, cardiology clinics, endocrinology specialists, and retail pharmacy consumers throughout India. Eris Lifesciences holds a market-leading position in India's domestic oral anti-diabetes and cardiovascular branded prescription drug market. The company is headquartered in Ahmedabad, India, and its equity shares trade on the BSE and National Stock Exchange of India.
3 of the funds FundTelligence covers report a position in Eris Lifesciences.
- Legal name
- Eris Lifesciences Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 3
Funds holding Eris Lifesciences
- Templeton Asian Smaller Companies Fund — Franklin Templeton · 1.38 % (full portfolio disclosed, September 2026)
- Templeton Emerging Markets Smaller Companies Fund — Franklin Templeton · 0.94 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)